ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury (AKI) and organ damage caused by inflammation and toxins. The Company is developing a platform of novel drugs targeting the dipeptidase-1 (DPEP1) inflammation pathway prevalent in the kidneys, lungs and liver. The Company is advancing a pipeline of drug candidates that includes LSALT peptide, a first-in-class inhibitor of the DPEP1 inflammation pathway, and cilastatin, a repurposed drug with off-target effects that help block toxin uptake into the kidneys - two approaches addressing distinct and urgent causes of AKI. The Company is ongoing Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide targeting cardiac surgery-associated acute kidney injury (CS-AKI). Cilastatin is particularly suited to preventing AKI caused by exogenous and endogenous toxins due to an off-target effect that blocks their uptake into the kidney tissue.